Editas Medicine, Inc.
NASDAQ Global Select•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Gilmore O'Neill M.D.
- Full Time Employees
- 246
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 11 Hurley Street Cambridge MA United States of America 02141
- IPO Date
- Feb 3, 2016
- CIK
- 0001650664
- Website
- editasmedicine.com
- Similar Companies
- Business
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Company News
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?
Editas Medicine Announces Chief Financial Officer Transition
Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026
Editas to reduce about 65% of its workforce over the next six months
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
Editas Stock Rises on Updated Data From SCD Study of Reni-Cel